Though major medical associations advise against prostate cancer screening in men over the age of 70, treatment in elderly populations costs Medicare more than $400 million a year, according to research published online Sept. 13 in JAMA Oncology. These costs include claims for CT, MRI and bone scans for diagnosis and follow-up imaging.